204 related articles for article (PubMed ID: 16008835)
1. Does alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women.
Sawka AM; Papaioannou A; Adachi JD; Gafni A; Hanley DA; Thabane L
BMC Musculoskelet Disord; 2005 Jul; 6():39. PubMed ID: 16008835
[TBL] [Abstract][Full Text] [Related]
2. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
Wells GA; Cranney A; Peterson J; Boucher M; Shea B; Robinson V; Coyle D; Tugwell P
Cochrane Database Syst Rev; 2008 Jan; (1):CD001155. PubMed ID: 18253985
[TBL] [Abstract][Full Text] [Related]
3. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial.
Ensrud KE; Black DM; Palermo L; Bauer DC; Barrett-Connor E; Quandt SA; Thompson DE; Karpf DB
Arch Intern Med; 1997 Dec 8-22; 157(22):2617-24. PubMed ID: 9531231
[TBL] [Abstract][Full Text] [Related]
4. Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies.
Boonen S; Laan RF; Barton IP; Watts NB
Osteoporos Int; 2005 Oct; 16(10):1291-8. PubMed ID: 15986101
[TBL] [Abstract][Full Text] [Related]
5. Vitamin K to prevent fractures in older women: systematic review and economic evaluation.
Stevenson M; Lloyd-Jones M; Papaioannou D
Health Technol Assess; 2009 Sep; 13(45):iii-xi, 1-134. PubMed ID: 19818211
[TBL] [Abstract][Full Text] [Related]
6. Effects of alendronate plus alfacalcidol in osteoporosis patients with a high risk of fracture: the Japanese Osteoporosis Intervention Trial (JOINT) - 02.
Orimo H; Nakamura T; Fukunaga M; Ohta H; Hosoi T; Uemura Y; Kuroda T; Miyakawa N; Ohashi Y; Shiraki M;
Curr Med Res Opin; 2011 Jun; 27(6):1273-84. PubMed ID: 21554143
[TBL] [Abstract][Full Text] [Related]
7. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women.
Cranney A; Wells G; Willan A; Griffith L; Zytaruk N; Robinson V; Black D; Adachi J; Shea B; Tugwell P; Guyatt G;
Endocr Rev; 2002 Aug; 23(4):508-16. PubMed ID: 12202465
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
Iwamoto J; Takeda T; Sato Y
Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
[TBL] [Abstract][Full Text] [Related]
9. [Meta-analysis of alendronate preventing hip fracture risk of postmenopausal women].
Yuan T; Li XL; Zhang CQ; Shi HP; Zeng BF
Zhonghua Yi Xue Za Zhi; 2009 Jun; 89(23):1620-2. PubMed ID: 19957509
[TBL] [Abstract][Full Text] [Related]
10. Alendronate for osteoporosis. Safe and efficacious nonhormonal therapy.
Adachi JD
Can Fam Physician; 1998 Feb; 44():327-32. PubMed ID: 9512836
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial.
Schwartz AV; Bauer DC; Cummings SR; Cauley JA; Ensrud KE; Palermo L; Wallace RB; Hochberg MC; Feldstein AC; Lombardi A; Black DM;
J Bone Miner Res; 2010 May; 25(5):976-82. PubMed ID: 20200926
[TBL] [Abstract][Full Text] [Related]
12. Indirect comparison of teriparatide, denosumab, and oral bisphosphonates for the prevention of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis.
Zhang L; Pang Y; Shi Y; Xu M; Xu X; Zhang J; Ji L; Zhao D
Menopause; 2015 Sep; 22(9):1021-5. PubMed ID: 25944523
[TBL] [Abstract][Full Text] [Related]
13. Osteoporosis Treatment Efficacy for Men: A Systematic Review and Meta-Analysis.
Nayak S; Greenspan SL
J Am Geriatr Soc; 2017 Mar; 65(3):490-495. PubMed ID: 28304090
[TBL] [Abstract][Full Text] [Related]
14. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.
Black DM; Schwartz AV; Ensrud KE; Cauley JA; Levis S; Quandt SA; Satterfield S; Wallace RB; Bauer DC; Palermo L; Wehren LE; Lombardi A; Santora AC; Cummings SR;
JAMA; 2006 Dec; 296(24):2927-38. PubMed ID: 17190893
[TBL] [Abstract][Full Text] [Related]
15. Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass.
Recker RR; Kendler D; Recknor CP; Rooney TW; Lewiecki EM; Utian WH; Cauley JA; Lorraine J; Qu Y; Kulkarni PM; Gaich CL; Wong M; Plouffe L; Stock JL
Bone; 2007 Apr; 40(4):843-51. PubMed ID: 17182297
[TBL] [Abstract][Full Text] [Related]
16. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group.
Black DM; Thompson DE; Bauer DC; Ensrud K; Musliner T; Hochberg MC; Nevitt MC; Suryawanshi S; Cummings SR;
J Clin Endocrinol Metab; 2000 Nov; 85(11):4118-24. PubMed ID: 11095442
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of bisphosphonates against osteoporosis in adult men: a meta-analysis of randomized controlled trials.
Chen L; Wang G; Zheng F; Zhao H; Li H
Osteoporos Int; 2015 Sep; 26(9):2355-63. PubMed ID: 25944731
[TBL] [Abstract][Full Text] [Related]
18. [Drug therapy for prevention of falls and fractures].
Ringe JD
Med Klin (Munich); 2006 Jun; 101 Suppl 1():1-5. PubMed ID: 16826362
[TBL] [Abstract][Full Text] [Related]
19. Alendronate for fracture prevention in postmenopause.
Holder KK; Kerley SS
Am Fam Physician; 2008 Sep; 78(5):579-81. PubMed ID: 18788232
[TBL] [Abstract][Full Text] [Related]
20. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX.
Kanis JA; Johansson H; Oden A; McCloskey EV
Bone; 2009 Jun; 44(6):1049-54. PubMed ID: 19254788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]